Introduction
HLA matching for hematopoietic stem cell transplantation is currently based on antigen or allele identity between donor and recipient. Strategies for selecting a partially HLA-mismatched donor vary when a full match cannot be identified. Some of these strategies have been based on the theory that selection for HLA-A and HLA-B mismatches with antigenic similarity would evoke less allorecognition and immune activation and would constitute a permissive mismatch.
The acronym HLA CREG (cross-reactive group) describes operationally monospecific HLA antisera that react with 2 or more HLA antigens (Table 1) . [1] [2] [3] This serologic cross-reactivity is now ascribed to determinants (public epitopes) that are differentially shared among HLA class I gene products. HLA-A and HLA-B gene products can be grouped into 8 or more families of CREG based upon serologic cross-reactivity patterns, 1 associative analyses, 4,5 or shared amino acid sequence polymorphisms. 6 Potential donor and recipient pairs may be matched for public epitopes even though they are mismatched for the private epitopes that confer unique differences between class I HLA molecules. Thus, there are levels of immunologic matching of HLA gene products ranging from the allele level, in which all public and private epitopes are matched, to the CREG level, in which public epitopes are matched but private epitopes are mismatched. 7 In the United States, CREG matching has been introduced as a possible approach to increase the opportunity of a renal recipient to receive a "well-matched" kidney 8 and to reduce the number of transplant rejections. 9 This strategy is controversial, however, since European multicenter studies and a single US center study report no beneficial effect of CREG matching. [10] [11] [12] [13] It is unclear whether similar results may hold in hematopoietic stem cell transplantation because of the different set of risks involved (eg, graft-versus-host disease and disease relapse).
Studies of the influence of CREG in bone marrow transplantation are very limited. Studies of partially matched donors suggest that some degree of HLA mismatch may be tolerated. 14, 15 A single study from the University of Minnesota examined differences between mismatches within or outside of CREG groups and did not find differences in outcome, 16 but the power was limited by small numbers. Based on the theoretical distinctions previously discussed, some transplantation centers have accepted a mismatch within a CREG while rejecting those with mismatches outside of a CREG, or have prioritized a mismatch within a CREG over a mismatch outside of a CREG. This study was designed to test the hypothesis that mismatched HLA-A or HLA-B antigens within a CREG group ("minor") lead to a better transplantation outcome than mismatched antigens outside of the CREG groups ("major") in hematopoietic stem cell transplant pairs matched for HLA-DRB1 alleles.
Patients, materials, and methods

Donor and recipient characteristics
This study included bone marrow and peripheral blood transplant pairs from 108 transplantation centers affiliated with the National Marrow Donor Program (NMDP) for which clinical outcome and retrospective highresolution HLA typing data were available (n ϭ 2709). All surviving recipients included in this analysis were retrospectively contacted and provided informed consent for participation in the NMDP research program, in accordance with the Declaration of Helsinki. Informed consent was waived by the NMDP institutional review board for all deceased recipients. To address bias introduced by inclusion of only a proportion of surviving patients (those who consented) but all deceased recipients, a sample of deceased patients was selected using a weighted randomized scheme that adjusts for overrepresentation of deceased patients in the consented cohort. Patients underwent transplantation in centers using their local protocols for conditioning regimen and graft-versus-host disease (GvHD) prophylaxis. Most of the patients (2221; 82%) received total body irradiation with a median dose of 1320 cGy (range, 550-1800 cGy).
Recipient outcomes were reported to the NMDP Coordinating Center by the transplantation centers using standardized forms submitted at the time of transplantation (baseline), at 100 days, at 6 months, and annually thereafter. Computerized validation was used to check the data for consistency as it was entered into the database. Routine data audits of the transplantation centers were performed to ensure the information reported to NMDP was consistent with the medical records.
HLA assignments
At the time of the transplantation, donors and recipients were, at a minimum, typed serologically for HLA-A, HLA-B, and HLA-DR antigens. NMDP required that the transplantation centers resolve the assignments at the level of all well-defined subtypic specificities. 17 Final donor selection was determined by each transplantation center based on its own criteria and on the minimum criterion established by the NMDP of a 5/6 antigen match at HLA-A, HLA-B, and HLA-DR. The donor and recipient HLA types were confirmed using pretransplantation blood samples collected by the NMDP and stored at the NMDP Research Sample Repository. All pairs were retrospectively high-resolution HLA typed for HLA-A, HLA-B, HLA-C, and HLA-DRB1 using DNA sequencing and sequence-specific DNA probes. 18, 19 For comparison and analysis of CREG matching, the high-resolution HLA data were converted to serologic equivalents. 20, 21 The extents of allele matching for study populations are described in Tables 2-3 .
CREG matching
Three published CREG schemes (Rodey et al 2 and Rodey 3 ; Takemoto 6 ; and Thompson et al 22 ) were used in the analyses. CREGs associated with the recipient and with the donor HLA-A and HLA-B antigens were evaluated by computerized algorithms. Cases in which a CREG was associated with a donor phenotype but was missing in a recipient were considered a major mismatch in the analysis of engraftment; whereas a CREG present in a recipient and not in a donor was considered a major mismatch in the GvHD analysis (Table 1) . A mismatch in either direction was considered a major mismatch in the survival analysis. Approximately 85% of cases were HLA-A and HLA-B matched at allele level, and about 5% to 6% were classed as minor mismatches and 8% to 9% as major mismatches. The gamma statistic that measures association between the scores on a scale of 0 to 1 was larger than 0.99 for all pair-wise comparisons.
Statistical methods
Data from each transplantation were collected prospectively from each transplantation center on standardized forms. Data were validated by the NMDP for accuracy and consistency. Time to neutrophil engraftment was defined as the first day of 3 consecutive laboratory values at or above 0.5 ϫ 10 9 cells/L. A severity grade was calculated for acute GvHD according to the reported stages of skin, liver, and intestinal involvement. 23 Univariate analyses were performed on the HLA-matched and -mismatched pairs (Table 4) . Survival rates were calculated by the method of Kaplan-Meier 24 and compared using the log-rank statistic. 25 Rates of engraftment and GvHD were calculated by cumulative incidence, 26 treating death from any cause as a competing risk and censored at the date of second transplantation. Cumulative incidences were compared at a particular time point (28 days for engraftment, 100 days for acute GvHD, and 2 years for chronic GvHD) using a first-order Taylor series to estimate the variance. 27 Multivariate analyses were performed using logistic regression for engraftment and the proportional hazards regression model 28 for survival and GvHD. Each regression model was adjusted for diagnosis and HLA matching as categorized in Tables 2 and 3 , respectively. HLA-A and HLA-B For personal use only. on July 15, 2017. by guest www.bloodjournal.org From allele matching was treated as one risk factor with cases classified as a match, a minor mismatch, or a major mismatch. Additional risk factors were included in the regression model if the Wald chi-square statistic yielded a P value less than .05. Factors considered were HLA-C match, disease, disease status, cell sources, recipient and donor age, sex, CMV serology, race, interval from diagnosis to transplantation, T-cell depletion, total body irradiation, and year of transplantation. Adjustment for center-specific effects had no impact on the outcomes and was not included in the model.
For each outcome, separate regression models were run for each definition of CREG groups considered in this study. Due to nonlinear effects, the continuous variables-recipient age and interval from diagnosis to transplantation-were categorized into discrete groups. The Acute lymphoblastic leukemia 637 (24) 523 (23) 39 (29) 75 (29) First CR 161 (6) 136 (6) 13 (10) 12 (5) Second CR 224 (8) 181 (8) 9 (7) 34 (13) Third or higher CR 81 (3) 62 (3) 8 (6) 11 (4) Relapse § 171 (6) 144 (6) 9 (7) 18 (7) Myelodysplastic disorders 246 (9) 217 (9) For personal use only. on July 15, 2017. by guest www.bloodjournal.org From effect of interval from diagnosis to transplantation was modeled separately for each diagnosis. All analyses were performed using the SAS statistical software (version 9.1; SAS Institute, Cary, NC).
Results
Demographics and CREG matching
The demographics of the study population were stratified by minor versus major mismatches as defined by the Rodey CREG algorithm (Table 2 ). There were no differences between minor and major mismatches within any of the 3 CREG schemes.
HLA-A and HLA-B locus mismatches totaled 396 (Table 3) . Minor mismatches at the HLA-A locus were 21%, 29%, and 26% of the total mismatches as defined according to the CREG models of Rodey et al 2 and Rodey 3 ; Takemoto 6 ; and Thompson et al 22 , respectively; minor mismatches at the HLA-B locus were 14%, 13%, and 11%, respectively. The analyses using the Rodey scheme are shown in this report. The results obtained with the other 2 classifications, Thompson et al 22 and Takemoto, 6 were similar (data not shown). Additionally, analyses were repeated on each outcome testing minor versus major separately in HLA-A and in HLA-B mismatches and no differences were detected (some data not shown). Because of the large number of comparisons involved, P values higher than .01 were not considered statistically significant.
Engraftment
There was no significant difference between minor and major mismatches for engraftment in univariate analysis (85% with 95% CI: 79%-90% vs 82% with 95% CI: 76%-88%). Engraftment was significantly better in HLA-A-and HLA-B-matched cases (90% with 95% CI: 88%-91%). Logistic regression found no significant effect of major mismatches compared with minor mismatches (P ϭ .67).
Acute graft-versus-host disease
As shown in Figure 1A , the cumulative incidence curves of acute GvHD grades III to IV showed no significant difference between minor and major mismatches (46% with 95% CI: 39%-52% vs 41% with 95% CI: 33%-48%). Evaluation of grades II to IV (Table 4) showed similar results (62% with 95% CI: 55%-69% vs 54% with 95% CI: 47%-62%). HLA-A-and HLA-B-matched cases showed a significantly reduced incidence (grades III-IV: 30% with 95% CI: 28%-32%; grades II-IV: 50% with 95% CI: 48%-52%) (Table 4) . A proportional hazards regression model of grades III to IV acute GvHD (Table 5 ) also showed no significant difference between minor and major mismatches (P ϭ .44 and P ϭ .78 for grades II-IV and III-IV, respectively). For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
Chronic GvHD
There was no difference between minor and major mismatches for chronic GvHD in univariate analysis (39% with 95% CI: 32%-46% vs 40% with 95% CI: 32%-48%) (Table 4) . A proportional hazards regression also showed no significant effect of major mismatches compared with minor mismatches (P ϭ .44).
Survival
Five-year overall survival was significantly better in HLA-A-and HLA-B-matched cases (36% with 95% CI: 34%-38%), but there were no significant differences between minor and major mismatches (21% with 95% CI: 15%-27% vs 26% with 95% CI: 21%-32%) as shown in Table 4 and Figure 1B . These results were confirmed in a multivariate regression model (Table 5 ). There were no detectable differences in 5-year overall survival between minor or major among HLA-A mismatches (22% with 95% CI: 15%-31% vs 30% with 95% CI: 23%-37%) or HLA-B mismatches (18% with 95% CI: 10%-27% vs 21% with 95% CI: 14%-29%). There were no significant differences between minor and major mismatches in the reported primary or secondary causes of death.
T-cell depletion
T-cell depletion has been used to reduce GvHD occurring as a consequence of HLA mismatching. 29 In the multivariate analyses, an interaction between T depletion and CREG was tested where appropriate (engraftment, GvHD); no significant effect was found (P ϭ .2 for engraftment; P ϭ .15 for both acute and chronic GvHD).
Analysis of CML group
When the analyses were restricted to the 1071 chronic myelogenous leukemia (CML) cases comprising the largest disease group (40%), results were similar to the analyses of the entire dataset. HLA-A and HLA-B matches had significantly better outcome than mismatches, but there were no detectable differences between minor and major mismatches regardless of which definition of CREG was used. Five-year overall survival rates were 44% (95% CI: 41%-47%), 25% (95% CI: 15%-37%), and 31% (95% CI: 22%-41%) for HLA-A and HLA-B matches; minor mismatches; and major mismatches, respectively. NA indicates not applicable. *Acute GvHD model was stratified on disease, T depletion, and year of transplantation. It was adjusted for radiation in the conditioning regimen (P ϭ .311) and cell source (P Յ .001).
†No significant interaction was detected between HLA-C and CREG matching (grades III-IV GvHD, P ϭ .53; overall survival, P ϭ .25). ‡Overall survival model was stratified on patient age and sex match. It was adjusted for race (P ϭ .002), donor-patient CMV status (P Ͻ .001), Karnofsky/Lansky score at transplantation (P Ͻ .001), disease (P Ͻ .001), and disease stage (P Ͻ .001). 
